Carl Zeiss Meditec AG share

Investing in Carl Zeiss Meditec AG is an investment in the future of the health sector. We drive the development of leading-edge technology and make it available for applications in the field of: ophthalmology, neurosurgery, ENT surgery, dental applications and systems for intraoperative radiotherapy.

Quotes, Charts & Orderbook

Security Identification Numbers

Stock exchange abbreviation

AFX

ISIN

DE0005313704

Reuters Identification Code (RIC)

AFXG.F (exchange floor)
AFXG.DE (XETRA)

Bloomberg

AFX GR

Key Facts at a Glance

  • ISIN

    DE0005313704

    Trading Segment

    Prime Standard

    Designated Sponsors

    ODDO BHF Corporates & Markets AG

    Paying Agent

    Commerzbank AG

    Share Capital

    €89,440,570.00

    Admitted Capital

    €89,440,570.00

    Category and Nominal Value

    No-par value bearer shares at a nominal value of €1.00 per share

    Stock Markets

    Deutsche Börse in Frankfurt (XETRA and exchange floor, “Parkett”)
    Regional stock exchanges in Berlin, Bremen, Düsseldorf, Hamburg, Munich and Stuttgart

    Capital Measures

    23-Mar-2017:
    Increase of the share capital of €89,309,610.00
    against cash contribution by €8,130,960.00 (approx. 10%) to
    €89,440,570.00; subscription rights of shareholders were excluded.

    26-Oct-2006:
    Increase of the share capital of €32,523,844.00 (divided into 32,523,844 no-par value shares) by €48,785,766.00 to €81,309,610.00 (divided into 81,309,610 no-par value shares); capital increase with subscription rights and against contributions in kind and cash contributions.

    10-May-2005:
    Increase of the share capital of €29,682,182.00 against cash contribution by €2,841,662.00 (approx. 10%) to €32,523844.00; subscription rights of shareholders were excluded.

    01-Feb-2005:
    Increase of the share capital of €28,416,628.00 against contribution in kind by €1,265,553.00
    (4.45%) to €29,682,182.00; subscription rights of shareholders were excluded;
    capital increase was part of the acquisition of the majority holding in IOLTech S.A.

    18-Sep-2003:
    Increase of the share capital of €25,833,300.00 against cash contribution by €2,583,329.00
    (10%) to €28,416,629.00; subscription rights of shareholders were excluded.

  • 2023/24
    2022/23
    2021/22
    2020/21
    2019/20
    2018/19

    XETRA

    Year-end price (EUR)1

    71.15

    82.82

    107.45

    166.05

    108.00

    104.60

    Year high (EUR)2

    123.75

    142.75

    191.05

    199.05

    121.40

    108.70

    Year low (EUR)2

    54.60

    78.66

    101.75

    105.14

    69.70

    61.00

    Year average (EUR)
     

    86.56

    115.18

    141.67

    142.65

    98.18

    81.80

    Daily order book turnover (XETRA) in fiscal year

    EUR

    15,367,421

    14,817,336

    16,090,137

    13,264,306

    Shares
      

    155,647

    104,284

    109,627

    105,938

    167,107

    162,154

    Number of shares as of 30 September
    (million shares)

    89.4

    89.4

    89.4

    89.4

    89.4

    89.4

    Market capitalization as of 30 September
    (million EUR)

    5,075.8

    7,511.2

    9,610.40

    14,851.60

    9,659.6

    9,355.5

    Earnings per share (EUR)

    2.01

    3.25

    3.29

    2.64

    1.37

    1.79

    Dividend per share (EUR)

    0.603

    1.10

    1.10

    0.90

    0.5

    0.65

    Dividend yield (%)4

    0.8

    1.3

    1.0

    0.5

    0.5

    0.7

  • Bank/Analyst

    Current Rating

    Date

    Price Target

    ALPHAVALUE
    Anas Patel

    Buy

    06-08-2024

    €97.40

    Bank of America
    Julien Ouaddour

    Hold

    18-07-2024

    €70.00

    Berenberg Bank
    Sam England

    Hold

    06-12-2024

    €66.00

    Deutsche Bank AG
    Falko Friedrichs

    Hold

    09-08-2024

    €66.00

    DZ Bank
    Sven Kürten

    Hold

    03-07-2024

    €68.00

    EQUI.TS GmbH
    Thomas Schießle

    Hold

    18-07-2024

    €105.00

    Equita
    Davide Marchesin

    Hold

    08-08-2024

    €70.00

    Goldman Sachs
    Richard Felton

    Sell

    23-09-2024

    €54.00

    Hauck & Aufhäuser
    Alexander Galitsa

    Buy

    23-09-2024

    €90.00

    HSBC
    Sezgi Oezener

    Hold

    20-06-2024

    €74.00

    JPM
    Anchal Verma

    Underweight

    03-12-2024

    €45.00

    Kepler Cheuvreux
    Oliver Reinberg

    Hold

    10-09-2024

    €62.00

    LBBW
    Volker Stoll

    Buy

    17-06-2024

    €92.00

    Metzler
    Alexander Neuberger

    Buy

    17-09-2024

    €104.00

    mwb research
    Harald Hof

    Buy

    07-08-2024

    €78.00

    ODDO BHF
    Oliver Metzger

    Neutral

    05-08-2024

    €70.00

    RBC
    Jack Reynolds-Clark

    Outperform

    06-12-2024

    €85.00

    Stifel
    Dylan Van Haaften

    Sell

    27-09-2024

    €60.00

    UBS
    Graham Doyle

    Neutral

    08-08-2024

    €71.00

    Please note: Banks and securities firms use different terms for their equity ratings. The information contained in the table is based on publicly available sources that we consider reliable but for which we do not assume any liability.

    In particular, we do not guarantee that the information is complete, accurate or up-to-date. All ratings are based on opinions given by the analysts in question. These do not necessarily reflect the opinion of Carl Zeiss Meditec AG. The assessments may change at any time without prior notice. Exemption from liability applies to Carl Zeiss Meditec AG; it does not refer to the correct rendering of the information based on external sources, in particular public sources.

    Analyst assessments relating to Carl Zeiss Meditec AG shares are only revised each quarter and are therefore not continually updated.
      

  • ZEISS Shareholder Structure

    ZEISS Shareholder Structure

    Carl Zeiss Meditec AG's subscribed capital is composed of 89,440,570 ordinary shares, each with a theoretical par value of €1 per share. The ZEISS Group holds around 59% of the shares. According to our knowledge, the remaining 41% are in free float.

Request investor information

Investor Update

Form is loading...

Your data

If you want to have more information on data processing at ZEISS please refer to our data privacy notice.


  • 1

    30 September.

  • 2

    XETRA closing price.

  • 3

    Amounts suggested by the Supervisory Board and the Executive Board of the Carl Zeiss Meditec AG.

  • 4

    Untill FY 2016/17 ratio of dividend per share to opening price for the respective fiscal year, from FY 2017/18 ratio of dividend per share to closing rate on 30 September.